womens health care  product innovation  cianna medical board of directors board of directors about cianna medical company profile management team board of directors careers contact product innovation is always topofmind jill anderson jill anderson brings more than two decades of leadership and entrepreneurship in oncology services and medical devices to her role as president and ceo of cianna medical she previously served as president of biolucent where she oversaw the rapid sales growth of the mammopad breast cushion and biolucent’s ascendant profile in women’s health care through the company’s acquisition by hologic inc in  prior to joining biolucent she served as vice president cancer services at lehigh valley hospital and health network where she led the expansion of the medical oncology service that doubled revenue and implemented several new areas of service into the hospital’s cancer care program as vice president eastern region for salick health care she was responsible for the company’s entry in the new york city market tiba aynechi phd ms aynechi is a partner in novo ventures novo as she has more than  years of combined research and banking experience in life sciences that spans various therapeutic areas and technology platforms prior to joining novo as ms aynechi was a director with burrill  company where she has completed regional and crossborder ma licensing and financing transactions for biotech and large pharmaceutical companies ms aynechi received her phd from the graduate group in biophysics at the university of california san francisco where her research involved developing computational methods for drug discovery she has an undergraduate degree in physics from the university of california irvine ms aynechi is also a published author of scientific articles and book chapters in the area of rational drug design gordon busenbark mr busenbark has over  years of global experience in the life sciences industry prior to joining cianna medical he spent  years at baxter healthcare his experience at baxter included seven years working as cfo of immuno ag in vienna austria he also spent five years as president of baxter’s global plasma therapuetics business more recently mr busenbark has served as cfo of three smaller life science companies – encysive pharmaceuticals xytis pharmaceuticals and inspiration biopharmaceuticals mr busenbark currently serves as chief financial officer for cianna medical cherrill farnsworth ms farnsworth is president and ceo of healthhelp the first company to offer benefits management for radiology and oncology services healthhelp has been named to the inc  list of fastestgrowing private companies nine times since the year  ms farnsworth is an influential national expert on changing health care regulations and regularly advocates radiology management and health care reform before the centers for medicare and medicaid services as well as other congressional and regulatory bodies farnsworth is a member of the national quality forum and serves on several boards including the american association of ppos she also serves on the faculties of the radiological society of north america and american healthcare radiology administrators and on the editorial advisory boards of imaging economics and advanced imaging nancy olson ms olson has been a venture capitalist for  years she is the founder and managing partner of fog city fund a venture fund that invests in life science and medical companies she was previously a general partner at st paul venture capital and sequoia capital she has invested in over  medical and life sciences companies she has served as a trustee of uc berkeley foundation and of hampshire college a director of the san francisco opera association and a board member of girl scouts of san francisco bay area she is currently a member on university of california innovation council established in  by uc president napolitano to facilitate technology transfer of uc technology and innovations into the state and wider community she chairs a workgroup for the committee as well as numerous initiatives on the uc berkeley campus david renzi david m renzi has over  years of experience in the healthcare sector most recently he was the ceo of carbylan therapeutics a publicly traded company focused on the development of a next generation injectable for treating osteoarthritis pain prior to this he was the ceo of neomend a commercial developer of sealants and adhesion barrier products utilizing hydrogel technology david was also the worldwide vice president of sales and marketing and chief commercial officer for novacept and surgrx both privately held venturebacked companies with successful exits he spent the early half of his career at the ethicon and ethicon endosurgery divisions of johnson and johnson where he was given responsibility for numerous business disciplines to include sales sales management marketing management and new procedure development zack scott md dr scott joined saints capital in  and is a vice president focused on healthcare opportunities he is currently a board member at cianna medical and visioncare prior to saints dr scott was at burrill  co where he made healthcare investments for three and a half years dr scott has invested in the areas of medical devices health care services diagnostics and biopharmaceuticals previously dr scott was a general surgery resident at oregon health science university in portland oregon dr scott has a ba in economics from duke university an md from the university of texas health science center at san antonio and an mba and a certificate in health sector management from the fuqua school of business at duke university where he was fuqua scholar dr scott is a member of the alpha omega alpha medical honor society tom umbel mr umbel has more than  years of medical device and diagnostics leadership experience mr umbel has lead a startup company through a successful acquisition and managed large organizations through significant growth he is currently vice president of business development for bioventus a privately owned orthobiologics company spun out from smith  nephew prior this mr umbel was group senior vice president corporate development and marketing for hologic inc the largest dedicated women’s health company in the us latest research  news press cianna medical honored with gold  medical design excellence award for scout® news st century approaches for advancing breast cancer care research strutbased apbi report of treatment results for  consecutive patients at  years from a multicenter retrospective study targeted breast conserving options start here let us know how to contact you if you would like to learn more about savi scout and savi brachy you can also opt to receive the latest news and research directly to your inbox first namelast nameorganization namephoneemail addresscityzipproductsservices of interest scout savi brachy training newsletter this iframe contains the logic required to handle ajax powered gravity forms the team  novo holding as we use cookies on this website by using the website you accept our use of cookies accept the team dedicated professionals we’re a team of dedicated professionals with wideranging expertise from pharmaceutical sciences biotech business and venture investment we draw on our professional experience and extensive network to share insights and provide guidance to our portfolio companies and as a small team we’re quick to respond when the right investment opportunities emerge department fielddepartment management team executive office people  organisation principal investments novo ventures novo ventures us inc seed investments finance  operations anne marie astrupgaard coordinator novo ventures anne marie joined novo ventures in  as venture coordinator  she assists with the administration and support for novo ventures anne marie has several years of experience within the venture and financial sector where she had worked in various positions as pa to executive management anne marie is educated legal secretary holds a mini mba and classes in organisation and project management  luk tiba aynechi partner novo ventures us inc tiba joined novo ventures us inc in san francisco california in  she is a member of the board of directors of anaptysbio inc arcellx inc nkarta inc cianna medical inc irhythm technologies inc battersea and spruce biosciences previously she was a board member of thesan pharmaceuticals inc tiba has more than  years of combined research and banking experience in life sciences that spans various therapeutic areas and technology platforms prior to joining novo ventures us inc tiba was a director with burrill  company where she has completed regional and crossborder ma licensing and financing transactions for biotech and large pharmaceutical companies tiba received her phd from the graduate group in biophysics at the university of california san francisco where her research involved developing computational methods for drug discovery she has an undergraduate degree in physics from the university of california irvine tiba is also a published author of scientific articles and book chapters in the area of rational drug design   anaptysbio inc arcellx inc battersea biotech cianna medical irhythm spruce biosciences luk scott a beardsley senior partner novo ventures us inc scott joined novo ventures us inc in san francisco california in  previously he was a board member of aerocrine ab from  scott was part of novo as’ growth equity team prior to joining novo as he was a managing director at jp morgan in san francisco heading the firms west coast biopharmaceuticals effort previous to that scott led piper jaffrays us biopharmaceuticals investment banking practice and was a member of the health care group at montgomery securities during his tenure as an investment banker scott originated and executed numerous transactions scott holds an mba from uclas anderson graduate school of management and a bs from colorado state university inogen inc luk peter tuxen bisgaard senior partner novo ventures us inc peter joined novo ventures us inc in san francisco california in  and in boston massachusetts in   he is on the board of directors of ra pharmaceuticals inc nasdaq rarx and htg molecular diagnostics inc nasdaqhtg both publicly listed companies and a number of privately held companies see below previously he was a board member of nevro nyse nvro otonomy nasdaq otic and alder nasdaq aldr among others from  peter was employed with novo as as a partner in novo ventures prior to joining novo as he was with mckinsey  co as a general consultant and as a specialist within the scandinavian corporate finance and strategy group at mckinsey peter focused on strategy development mergers acquisitions and alliances in various industries he has bsc and msc in engineering from the technical university of denmark and a post graduate degree in mathematical modelling in economics by the european consortium for mathematics in the industry   anokion sa bolt therapeutics entasis therapeutics htg molecular diagnostics inc kanyos bio outpost medicine ra pharmaceuticals inc luk raymond camahort associate novo ventures us inc ray joined novo ventures us inc in boston massachusetts in  he has over  years of research and business development experience with expertise in biochemistry molecular biology and genetics ray was an associate at the harvard university office of technology development where he worked to commercialize technologies developed in both chemistry and stem cellregenerative biology ray completed a national institute of health nih postdoctoral training fellowship at harvard university while concurrently holding a business development position at partners healthcare research ventures and licensing ray was a predoctoral fellow at the stowers institute for medical research in kansas city missouri  he holds a phd from the university of kansas in biochemistry and molecular biology and a bs in biological sciences from the university of california santa barbara  luk thomas dyrberg managing partner novo ventures thomas joined novo as in  he is a member of the boards of directors of galera therapeutics inc nuvelution pharma inc ophthotech corporation and panoptica inc thomas held research positions at the hagedorn research institute denmark and at the scripps research institute la jolla usa in  he joined novo nordisk as initially working in health care discovery on various aspects of diabetes immunology and pathogenesis and from  in health care clinical drug development thomas obtained an md degree from the university of copenhagen in  and a dmsc degree also from the university of copenhagen in  galera therapeutics inc nuvelution pharma inc ophthotech luk martin edwards senior partner novo ventures dr edwards joined novo as in  working out of the uk he is chairman of the board of directors of epsilon bio ltd and vantia therapeutics ltd and a member of the board of directors of acacia pharma ltd karus therapeutics ltd nuvelution pharma inc tarsa therapeutics inc verona pharma and fg  dr edwards also holds an adjunct professorship at copenhagen business school cbs simi from  dr edwards was the ceo of reneuron holdings taking that company public in  and raising a total of £m in equity and debt financing from  he was corporate vp and head of drug development for novo nordisk as where he was responsible for all aspects of preclinical and clinical drug development previously he worked for six years in the usa first as vp pharmacology and medical affairs of zymogenetics inc in seattle and then as senior vp for medical affairs at novo nordisk in princeton nj dr edwards trained in physiology and medicine in manchester he is a member of the royal colleges of physicians a member with distinction of the royal college of general practitioners a fellow of the faculty of pharmaceutical medicine and holds an mba from the university of warwick  acacia pharma colucid pharmaceuticals fg karus therapeutics ltd nuvelution pharma inc tarsa therapeutics inc vantia therapeutics ltd luk shawnalea frazier associate novo ventures us inc shawna joined novo ventures us inc san francisco california in  previously she served as executive director of business development at vxp pharma a service company facilitating contractual collaborations in discovery development and manufacturing in the life science industry in addition shawna was cofounder and scientific advisor of a bay area startup developing platform technology relevant to neurological and ocular indications her research experience spans the areas of cellular physiology and molecular engineering with applications to biological therapeutics and gene therapy shawna received her phd in biochemistry  molecular biophysics with an emphasis in neuroscience from the california institute of technology caltech prior to she earned combined bs and master’s degrees from kansas state university in biochemistry in an accelerated  year program luk danielle freitas venture coordinator novo ventures us inc danielle joined novo ventures us inc in san francisco california in  as venture coordinator  she assists with the administration and support for the san francisco office of novo ventures us inc danielle received a bachelor of arts degree from san francisco state university  before joining novo ventures us inc she worked for a capital management firm providing project and administrative support to the ceo and other members of the firm’s executive management team  luk kenneth harrison senior associate novo ventures us inc ken joined novo ventures us inc in san francisco california in  ken brings experience as a senior market planning manager at genentech where he helped guide strategic decision making for the ophthalmology and her franchises  prior to genentech ken worked as a management consultant at lek consulting and as the entrepreneurship program manager at qbmission bay capital where he helped create new programs to launch and support life sciences companies in the bay area ken studied cellular lipid storage and metabolism as an ap giannini foundation fellow at the j david gladstone institutes earned a phd in pharmacology from yale university and has a bs in molecular biology from texas tech university where he was a howard hughes medical institute undergraduate research fellow luk amy kacprowicz venture coordinator novo ventures us inc amy joined novo ventures us inc in boston massachusetts in  as venture coordinator  she assists with the administration and support for the boston office of novo ventures us inc amy received a bachelor of arts degree from hobart and william smith colleges  before joining novo ventures us inc she held various positions in healthcare administration providing project and administrative support  luk nilesh kumar partner novo ventures us inc nilesh joined novo ventures us inc in boston in  prior to joining novo nilesh was senior director at ms ventures where he invested in early stage life science companies nilesh led the initial investments and served on the boards of auxogyn canbex fstar raze therapeutics rana therapeutics padlock therapeutics and tocopherx in addition to his venture investment role nilesh has successfully led several strategic licensing transactions at merck serono in oncology and autoimmune therapeutic areas nilesh received his phd from the department of chemistry and chemical biology at harvard university he holds an mba from harvard university and did his undergraduate degree in natural sciences from the university of cambridge uk rgenix tarveda therapeutics luk jennifer lee associate novo ventures us inc jeni joined novo ventures us inc in boston ma in  previously jeni supported the director of research at aquilo capital management in san francisco ca where she helped assess investment opportunities of small cap biotech companies she also has experience in industry research having interned in the late stage product research and development group at genentech jeni was a cofounder of vivita technologies inc a cardiovascularfocused medtech startup with a platform to generate immunecompatible tissues from animal sources jeni earned her phd in biomedical engineering with a designated emphasis in biotechnology from the university of california davis where she studied functional cartilage tissue engineering she received her bs in bioengineering from the university of california berkeley luk junie lim us general counsel novo ventures us inc junie joined novo ventures us inc in  in san francisco ca as us general counsel  she helps to manage investment structuring and negotiation portfolio company management regulatory governance and other general legal matters prior to joining novo junie was counsel at wilson sonsini goodrich  rosati where she represented private and public biotech and technology companies and venture capital firms in financings mergers and acquisitions corporate governance recapitalizations and other stock related matters complex contract negotiations securities compliance and disclosures employment issues intellectual property issues and strategic partnerships junie holds a juris doctor from new york university school of law new york new york and a ba in economics from smith college northampton massachusetts   luk heather ludvigsen operations manager novo ventures heather is responsible for controlling the venture investments from a financial and administrative perspective prior to joining novo as in  heather spent seven years with brown brothers harriman  co first as head of the european internal audit function based in luxembourg and then as the investment management business line controller based in new york city prior to this heather was an audit manager and cpa with pricewaterhousecoopers in both luxembourg and boston heather holds a bs in accounting and a ba in business administration from the university of kansas luk nanna lüneborg principal novo ventures nanna joined novo as in  she spent the first four years with novo as as part of the seeds team where she helped build a strong portfolio of seed and series a stage companies primarily in scandinavia she led the initial investments and served on the boards of io biotech minervax and pcovery and as an observer with forendo and galecto nanna joined the ventures team in  she now serves on the boards of epsilon bio orphazyme and inventiva from  nanna was an associate with apposite capital a londonbased venture fund where she was part of the life science investment team and participated in both primary and secondary investments with multiple portfolio companies leading to highly successful exits for the fund earlier in her career she worked at cancer research uk as a research analyst and as a consultant to various biotech and healthcare venture projects during her mba nanna received her phd in neuroscience from university college london as a wellcome trust scholar she holds an mba with distinction from university of cambridge where she was a sainsbury scholar and a st class ba from university of oxford epsilon bio ltd inventiva orphazyme aps luk peter moldt partner novo ventures us inc peter joined novo ventures us inc in san francisco california in  he is chairman of the board of directors of allakos inc and a member of the board of directors of corvus pharmaceuticals inc bolt therapeutics escape bio spruce biosciences and tioma therapeutics previously he was a board member of cytochroma inc hemofocus aps neurokey as and orphazyme aps from  peter was employed with novo as as a partner in novo ventures in  peter cofounded curalogic as served as ceo until  and took the company public in  from  he was chief operating officer of tm pharma as which he also cofounded previously he worked for  years with neurosearch as where he was responsible for all aspects of preclinical and clinical drug development peter holds a phd in medicinal chemistry from the royal danish school of pharmacy he has also been a post doc with yale universitys department of organic chemistry   allakos inc bolt therapeutics corvus pharmaceuticals escape bio spruce biosciences tioma therapeutics luk eric shiozaki principal novo ventures us inc eric joined novo ventures us inc in san francisco california in  prior to joining novo ventures us inc eric was a director at apposite capital where he established the firm’s san francisco office and managed its secondary direct investment activity in the us he has also worked for vitapath genetics in business development and strategy and as an associate at burrill  company where he was a member of the firm’s venture capital practice before entering venture capital eric was a leukemia  lymphoma society postdoctoral fellow at ucla while conducting his postdoctoral research he also spent time in the university’s technology transfer office eric received a phd in molecular biology from princeton university and a ba in biophysics from johns hopkins university luk mathias vinther associate novo ventures mathias joined the novo ventures team as associate in september  where he will engage in deal flow activities and investment diligence as well as assist in portfolio management mathias holds a phd in nanomedicine with an emphasis in immunotherapy and drug delivery from aarhus university  during his education mathias has studied abroad at university of california berkeley and harvard medical school at harvard mathias was associated with the wyss institute for biological inspired engineering and danafarber cancer institute luk novo ventures us inc is a separate legal entity that provides certain consultancy services to novo as mainly within the areas of identifying analysing and negotiating various investment opportunities among life science and biotech companies in the us as well as certain followup activities related thereto such as board memberships financial control and reporting efforts   aynechi tiba — women vc search close menu search close menu women vc step up and stand out fund the change you want to happen active venture investor wwwnovodk send inmail education opportunities investment focus lifescience tiba aynechi is a partner at novo ventures us inc in san francisco california that she joined in  she is a member of the board of directors of anaptysbio inc arcellx cianna medical inc and irhythm technologies inc  previously she was a board member of thesan pharmaceuticals inc tiba has more than  years of combined research and banking experience in life sciences that spans various therapeutic areas and technology platformsprior to joining novo ventures us inc tiba was a director with burrill  company where she has completed regional and crossborder ma licensing and financing transactions for biotech and large pharmaceutical companiestiba received her phd from the graduate group in biophysics at the university of california san francisco where her research involved developing computational methods for drug discovery she has an undergraduate degree in physics from the university of california irvine tiba is also a published author of scientific articles and book chapters in the area of rational drug design update profile funds investment verticals biotechnology healthcare and life sciences with a focus on investments in products for diagnosis control treatment and prevention of disease development and application of biotechnology instruments and medical devices improvement of food nutrition and health for humans and animals and development of sustainable solutions for the environment  become a participating member all women vc a names jenny abramsonmilena adamiananika agarwaljulie allegronisa amoilschristine aylwardtiba aynechi subscribe for news  updates tiba aynechi  burrill  company  zoominfocom tiba aynechi  san francisco ca  intelius sign in we found tiba aynechi in san francisco ca tiba aynechi intelius found that tiba aynechi is a female between  and  years old from san francisco ca we have connected them to  addresses  phones and  relatives or associates get report now age tiba aynechi is in her s tiba has lived in san francisco ca aliso viejo ca oakland ca tibas relatives amir salek mohamad aynechi noyan aynechi mana aynechi tiba aynechi zodiac signvirgo genderfemale professional status postdoctoral fellow at university of california get report now want to know more about tiba get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about tiba or use our people search engine to find others get background check on tiba aynechi get a criminal check on tiba aynechi get a public record report on tiba aynechi get a people search report on tiba aynechi tiba aynechis contact information known cities lived in find out where tiba aynechi has lived as well as tiba aynechis phone numbers and email addresses tiba aynechi has lived in  states california address for tiba aynechi  t s san francisco ca has lived in san francisco ca aliso viejo ca get full address report phone numbers associated with tiba aynechi    irvine ca    san francisco ca    daly city ca get full phone report email addresses associated with tiba aynechi tacom ticom get email report tiba aynechis education information known schools attended learn about tiba aynechis academic history find out which schools tiba aynechi attended the dates attended as well as the degrees tiba aynechi received the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act tiba aynechi has attended  schools university of san francisco tiba aynechi has a phd in biophysics university of california  irvine tiba aynechi has a undergraduate degree in physics tiba aynechis professional information information regarding tiba aynechis professional history find out previous places tiba aynechi has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act tiba aynechi has worked at  places company university of california title postdoctoral fellow company irhythm technologies inc title director tiba aynechis experience title postdoctoral fellow company university of california job details the university of california opened its doors in  with just  faculty members and  students today the uc system includes more than  students and more than  faculty and staff with more than  million alumni living and working around the world for almost  years uc has expanded the horizons of what we know about ourselves and our world our campuses are routinely ranked among the best in the world but our reach extends beyond campus borders title director company irhythm technologies inc job details irhythm is a privately held digital healthcare company that aspires to be the world leader in cardiac arrhythmia information irhythm develops and commercializes fdacleared solutions that integrate consumerfriendly biosensor technology vast patient data powerful analytics and medical expertise its flagship solution the zio service offers a proven approach to longterm continuous monitoring that enables diagnosis earlier in the clinical pathway to improve patient outcomes and reduce healthcare costs additional professional information on tiba aynechi see tiba aynechis linkedin profile tiba aynechis social network and potential email matches find out potential social network profiles and potential email usernamed for tiba aynechi tiba aynechis known social networks and potential email matches find all of tiba aynechis social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches tiba aynechi username matches tibaaynechi aynechitiba tibaaynechi aynechitiba tibaaynechi aynechitiba tibaaynechi aynechitiba taynechi popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches t aynechi intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here active portfolio  selected companies  novo holding as we use cookies on this website by using the website you accept our use of cookies accept active portfolio  selected companies check the map to see where our portfolio companies are located and read about each one in the company profiles seed investments novo ventures principal investments   acacia pharma is focused on the development of compounds for the prevention and treatment of   acacia pharma is focused on the development of compounds for the prevention and treatment of nausea and vomiting following surgery and chemotherapy the lead programme is in phase  clinical development website view on map acacia pharma harston mill harston cambridge cb gg uk martin edwards senior partner novo ventures go to profile luk   acceleron pharma nasdaq xlrn is a clinicalstage biotechnology company developing ligand   acceleron pharma nasdaq xlrn is a clinicalstage biotechnology company developing ligand traps that target the endogenous ligands for the tgf superfamily of serinethreonine protein kinase receptors the company’s lead compound luspatercept is in phase  clinical trials for the treatment of anemia associated with myelodysplastic syndrome mds and thalassemia website view on map acceleron pharma  sidney street cambridge ma  usa luk   allakos develops monoclonal antibodybased therapies to target eosinophils and mast cells   allakos develops monoclonal antibodybased therapies to target eosinophils and mast cells the lead programme is in preclinical development website view on map allakos inc  shoreway road suite a san carlos ca  usa peter moldt partner novo ventures us inc go to profile luk   anaptysbio is an antibody therapeutics company and a leader in antibody discovery and   anaptysbio is an antibody therapeutics company and a leader in antibody discovery and optimisation website view on map anaptysbio inc  pacific center court suite  san diego ca  usa tiba aynechi partner novo ventures us inc go to profile luk   anokion develops novel peptide and protein therapeutic with very low immunogenicity the   anokion develops novel peptide and protein therapeutic with very low immunogenicity the company is focused on products for orphan diseases website view on map anokion sa epfl innovation park en ruchoz ch de la dent doche a ch ecublens switzerland peter tuxen bisgaard senior partner novo ventures us inc go to profile luk   apollo nasdaqapen markets orbera® and lapband® for the treatment of obesity the company   apollo nasdaqapen markets orbera® and lapband® for the treatment of obesity the company is a leader in flexible endoscopic surgery via overstitchtm and other endoscopic devices website view on map apollo endosurgery inc  s capital of texas hwy bldg  ste  austin tx  usa luk   battersea biotech develops alternative cell types and technologies to overcome the   battersea biotech develops alternative cell types and technologies to overcome the shortcomings of current cart and tcr technologies tiba aynechi partner novo ventures us inc go to profile luk   bolt therapeutics plans to develop a novel format for tcell mediated antitumour therapy   bolt therapeutics plans to develop a novel format for tcell mediated antitumour therapy peter tuxen bisgaard senior partner novo ventures us inc go to profile peter moldt partner novo ventures us inc go to profile luk   cianna medical is a medical device company that manufactures and markets the savi breast   cianna medical is a medical device company that manufactures and markets the savi breast brachytherapy applicator for the delivery of radiation after lumpectomy surgery website view on map cianna medical  journey suite  aliso viejo ca  usa tiba aynechi partner novo ventures us inc go to profile luk   corvus pharmaceuticals nasdaq crvs is developing drugs that harness the immune system to   corvus pharmaceuticals nasdaq crvs is developing drugs that harness the immune system to fight cancer in a new area of medicine known as immunooncology website view on map corvus pharmaceuticals  mitten road suite  burlingame ca  usa peter moldt partner novo ventures us inc go to profile luk   crispr therapeutics nasdaqcrsp is developing transformative genebased medicines for   crispr therapeutics nasdaqcrsp is developing transformative genebased medicines for patients with serious diseases the therapeutic approach is to cure diseases at the molecular level using the breakthrough gene editing technology called crisprcas website view on map crispr therapeutics  sidney st cambridge ma  usa luk   escape bio is developing a pipeline of apoe structure correctors for the treatment of   escape bio is developing a pipeline of apoe structure correctors for the treatment of neurodegenerative diseases including alzheimer’s disease peter moldt partner novo ventures us inc go to profile luk   entasis therapeutics is a spin out from astra zeneca the company is developing novel   entasis therapeutics is a spin out from astra zeneca the company is developing novel antibiotics for treatment of severe gramnegative infections the focus is on developing new antibiotics to treat infections resistant to current treatments website view on map entasis therapeutics gatehouse park biohub  gatehouse drive waltham ma  usa peter tuxen bisgaard senior partner novo ventures us inc go to profile luk   epsilon bio develops compounds targeting the removal of cellular debris in chronic   epsilon bio develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders the lead compound is in preclinical development website view on map epsilon bio ltd bridge houses  fiddle bridge lane hatfield hertfordshire al sp uk nanna lüneborg principal novo ventures go to profile luk   fg is focusing on the discovery and development of novel drugs to treat lifethreatening   fg is focusing on the discovery and development of novel drugs to treat lifethreatening fungal diseases website view on map fg lankro way eccles manchester m lx united kingdom martin edwards senior partner novo ventures go to profile luk   flexion nasdaq flxn is a specialty pharmaceutical company focused on the development and   flexion nasdaq flxn is a specialty pharmaceutical company focused on the development and commercialisation of novel local therapies for the treatment of patients with musculoskeletal conditions beginning with osteoarthritis oa – a type of degenerative arthritis website view on map flexion therapeutics luk   galera therapeutics is a clinicalstage company focused on the development of highly   galera therapeutics is a clinicalstage company focused on the development of highly selective small molecule dismutase mimetics targeting the prevention of radiationinduced mucositis website view on map galera therapeutics inc  west liberty boulevard suite  malvern pa  usa thomas dyrberg managing partner novo ventures go to profile luk   htg molecular diagnostics nasdaq htgm develops and sells its edge instrument and assays   htg molecular diagnostics nasdaq htgm develops and sells its edge instrument and assays for quantification of gene expression the instrument and assays are used for clinical diagnostics and in research the edge instrument is being launched in the us website view on map htg molecular diagnostics inc  e global loop tucson az  usa peter tuxen bisgaard senior partner novo ventures us inc go to profile luk   inventiva develops drugs targeting nuclear receptors transcription factors and epigenetic   inventiva develops drugs targeting nuclear receptors transcription factors and epigenetic modulators an has a clinical pipeline of novel breakthrough therapies against fibrotic diseases cancers and orphan diseases website view on map inventiva nanna lüneborg principal novo ventures go to profile luk   invuity nasdaq ivty is a commercial stage medical technology company pioneering the use of   invuity nasdaq ivty is a commercial stage medical technology company pioneering the use of advanced photonics to provide surgeons with improved direct visualisation of surgical cavities during minimally invasive and minimal access surgical procedures website view on map invuity luk   irhythm technologies nasdaq irtc is a medical device company that develops and markets the   irhythm technologies nasdaq irtc is a medical device company that develops and markets the zio® service – an innovative cardiac monitoring and diagnostic solution which uses a singleuse wearable patch to detect cardiac arrhythmias website view on map irhythm  townsend street suite  san francisco ca  usa tiba aynechi partner novo ventures us inc go to profile luk   kalvista pharmaceuticals nasdaq kalv develops plasma kallikrein inhibitors for the   kalvista pharmaceuticals nasdaq kalv develops plasma kallikrein inhibitors for the treatment of diabetic macular oedema their lead programme is in phase  clinical development website view on map kalvista luk   kanyos bio is a spin out from anokion the company has the rights to develop celiac disease   kanyos bio is a spin out from anokion the company has the rights to develop celiac disease and td autoimmune programmes and an option deal with astellas website view on map kanyos bio peter tuxen bisgaard senior partner novo ventures us inc go to profile luk   karus therapeutics develops innovative therapies for the treatment of inflammation and cancer   karus therapeutics develops innovative therapies for the treatment of inflammation and cancer the lead programmes are in preclinical development and focus on histone deacetylase and phosphoinositide kinase inhibitors website view on map karus therapeutics ltd  innovation drive milton park abingdon oxfordshire ox rz uk martin edwards senior partner novo ventures go to profile luk   merus nasdaq mrus is a dutch biotechnology company developing fully human bispecific   merus nasdaq mrus is a dutch biotechnology company developing fully human bispecific antibodies for various oncology treatments their two lead programmes are for solid tumors and aml website view on map merus padualaan   ch utrecht the netherlands luk   minerva surgical focuses on women’s healthcare currently minerva surgical’s development   minerva surgical focuses on women’s healthcare currently minerva surgical’s development projects are aimed at delivering next generation products for the treatment of abnormal uterine bleeding website view on map minerva surgical luk   nabriva therapeutics nasdaq nbrv is focused on the research and development of novel anti   nabriva therapeutics nasdaq nbrv is focused on the research and development of novel antiinfective agents to treat serious infections nabriva’s lead product candidate lefamulin is entering phase  clinical trials for the treatment of moderate to severe communityacquired bacterialpneumonia website view on map nabriva therapeutics leberstrasse   vienna austria luk   nuvelution leverages its extensive knowledge experience and relationships in the pharma and   nuvelution leverages its extensive knowledge experience and relationships in the pharma and biotech industries to deploy capital in risksharing collaborations with companies where product development can be facilitated by both capital and human resources with the goal of making this model an essential tool for pharma and biotech companies to bring products to the market website view on map nuvelution pharma inc  gateway boulevard suite  south san francisco ca  usa thomas dyrberg managing partner novo ventures go to profile martin edwards senior partner novo ventures go to profile luk   obseva develops innovative drugs for women’s reproductive medicine the lead project is in   obseva develops innovative drugs for women’s reproductive medicine the lead project is in phase  clinical development for enhancing embryo implantation and increasing the pregnancy rate in connection with assisted reproductive technologies website view on map obseva sa chemin des aulx   planlesouates geneva switzerland luk   orphazyme develops novel therapeutics for the treatment of lysosomal storage diseases the   orphazyme develops novel therapeutics for the treatment of lysosomal storage diseases the company is preparing the lead programme for a phase  registrationenabling clinical trial in niemannpick disease type c website view on map orphazyme aps ole maaløes vej  copenhagen n denmark nanna lüneborg principal novo ventures go to profile luk   outpost medicine is developing novel therapeutics for the treatment of urologic and   outpost medicine is developing novel therapeutics for the treatment of urologic and gynaecologic disorders op is currently in phase  for the treatment of stress urinary incontinence website view on map outpost medicine  hayden avenue lexington ma  usa peter tuxen bisgaard senior partner novo ventures us inc go to profile luk   panoptica is developing a novel topical drug for wet agerelated macular degeneration the   panoptica is developing a novel topical drug for wet agerelated macular degeneration the lead programme is in phase b clinical development website view on map panoptica inc  morristown road suite  bernardsville nj  usa luk   procept biorobotics develops a new treatment for benign prostate hyperplasia based on image   procept biorobotics develops a new treatment for benign prostate hyperplasia based on image guided and roboticallycontrolled water ablation of prostate tissue the device is ce marked and a pma study underway for us approval website view on map procept biorobotics  island dr suite  redwood shores ca  usa luk   ra pharmaceuticals nasdaq rarx develops drugs for treatment of complement dysregulation   ra pharmaceuticals nasdaq rarx develops drugs for treatment of complement dysregulation diseases the lead programme is an anti c complement inhibitor website view on map ra pharmaceuticals inc one kendall square building  west rd floor cambridge ma  usa peter tuxen bisgaard senior partner novo ventures us inc go to profile luk   reata pharmaceuticals nasdaq reta develops new drugs for the treatment of inflammatory   reata pharmaceuticals nasdaq reta develops new drugs for the treatment of inflammatory diseases and cancer the lead programmes are in phase  clinical development website view on map reata pharmaceuticals inc  gateway drive suite  irving tx usa luk   rgenix is developing firstinclass drugs that target key pathways in cancer progression   rgenix is developing firstinclass drugs that target key pathways in cancer progression website view on map rgenix  east th street new york ny  usa nilesh kumar partner novo ventures us inc go to profile luk   sibone is a revenuestage medical device company which develops and markets new therapies   sibone is a revenuestage medical device company which develops and markets new therapies for patients with low back pain related to sacroiliac joint disorders website view on map sibone  olin avenue suite  san jose ca  usa luk   spectranetics nasdaq spnc develops manufactures markets and distributes singleuse   spectranetics nasdaq spnc develops manufactures markets and distributes singleuse medical devices used in minimally invasive procedures within the cardiovascular system website view on map spectranetics luk   spruce biosciences is a clinicalstage biopharmaceutical company with programs in development   spruce biosciences is a clinicalstage biopharmaceutical company with programs in development to serve the chronic and acute needs of patients with orphan disease affecting the neuroendocrine axis website spruce biosciences tiba aynechi partner novo ventures us inc go to profile peter moldt partner novo ventures us inc go to profile luk   tarsa therapeutics develops an oral calcitonin for the treatment of osteoporosis   tarsa therapeutics develops an oral calcitonin for the treatment of osteoporosis website view on map tarsa therapeutics inc  penn center  john f kennedy boulevard suite  philadelphia pa usa martin edwards senior partner novo ventures go to profile luk   tarveda therapeutics is a preclinical stage biotechnology company that is developing novel   tarveda therapeutics is a preclinical stage biotechnology company that is developing novel drugs for the treatment of cancer website view on map tarveda therapeutics  coolidge avenue watertown ma  usa nilesh kumar partner novo ventures us inc go to profile luk   tioma is developing drugs for lifethreatening disorders driven by cdmediated signalling   tioma is developing drugs for lifethreatening disorders driven by cdmediated signalling pathways website view on map tioma therapeutics  forest park avenue suite  st louis mo  usa peter moldt partner novo ventures us inc go to profile luk   unchained labs develops and markets a broad range of life science instruments to analyse   unchained labs develops and markets a broad range of life science instruments to analyse protein stability and optimise protein formulations website view on map unchained labs inc  koll center parkway suite  pleasanton ca  usa luk   unum is developing antibodycoupled tcell technology platform to combine antibody with cart   unum is developing antibodycoupled tcell technology platform to combine antibody with cart killing mechanism for use in oncology website view on map unum therapeutics one broadway th floor cambridge ma  usa luk   vantia therapeutics develops small molecule agonists of vasopressin receptors the lead asset   vantia therapeutics develops small molecule agonists of vasopressin receptors the lead asset is in phase  clinical development for the treatment of nocturia website view on map vantia therapeutics ltd phi house enterprise road southampton science park southampton hampshire uk martin edwards senior partner novo ventures go to profile luk   verona pharma lse vrp is a clinical stage biopharmaceutical company focused on the   verona pharma lse vrp is a clinical stage biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs such as copd asthma and cystic fibrosis website view on map verona pharma luk   xenon pharmaceuticals nasdaq xene is a geneticsbased drug development company the lead   xenon pharmaceuticals nasdaq xene is a geneticsbased drug development company the lead compound is in clinical development for the treatment of pain website view on map xenon pharmaceuticals luk   laurence lasky bryant fong greg young tiba aynechi jackie tay pamela simonton kevin boggs hamish cameron geoffrey matus william white gordon nixon howard alper felix chee ron venter  genomeweb skip to main content rss feeds twitter linkedin log in join now business  policybusiness news research funding policy  legislation regulatory news reimbursement technologymicroarrays  multiplexing pcr informatics sequencing mass spec sample prep gene silencinggene editing researchgenetic research gene expression research epigenetics research proteomics  protein research cell biology research diagnosticsmolecular diagnostics companion diagnostics biomarker discovery  validation drug discovery  development clinical sequencing clinical proteomics disease areascancer infectious disease cardiovascular disease neurological  psychological disease metabolic disease autoimmune disease inherited disease reproductive health applied markets resourceswebinars white papers the scan career blog job listings new products people in the news conferences  events main menu enter your keywords home » laurence lasky bryant fong greg young tiba aynechi jackie tay pamela simonton kevin boggs hamish cameron geoffrey matus william white gordon nixon howard alper felix chee ron venter laurence lasky bryant fong greg young tiba aynechi jackie tay pamela simonton kevin boggs hamish cameron geoffrey matus william white gordon nixon howard alper felix chee ron venter jan   premium us venture partners said last week that laurence lasky has joined the firm as a venture partner   lasky was a founding scientist of genetics institute now part of wyeth pharmaceuticals lasky has also been a scientific fellow at bay area biotech genentech and founded latterell venture partners where he served as general partner from  to    get the full story with genomeweb premium only  for the first  days a trial upgrade to genomeweb premium gives you full site access interestbased email alerts access to archives and more never miss another important industry story try genomeweb premium now already a genomeweb premium member login now or see if your institution qualifies for premium access before your trial expires we’ll put together a custom quote with your longterm premium options not ready for premium register for free content you can still register for access to our free content breaking news exact sciences q revenues up  percent lateonset preeclampsia markers proposed from proteomic study genetic predisposition to high blood calcium linked to increased heart disease risk nih selects community partners to promote precision medicine initiative roche includes cobas hivhiv test in global access program waters q revenues grow  percent the scan french funding agency head resigns the president of frances national research agency has resigned according to nature news right to try versus clinical trials a senator wants a righttotry provision in the us food and drug administration funding bill but an ethicist says at stat news that it would undermine the role of clinical trials this week in pnas in pnas this week red algae porphyra umbicalis genome deep neural network model for sequencing peptides and more lifestyle zone the guardians barbara ellen has tried out some dna testing services to see whether they provide valuable information sponsorships about us advertise contact jobs subscribe privacy policy  copyright   genomeweb llc  all rights reserved irhythm technologies announces tiba aynechi to its board after closing m series e financing led by novo as email protected twitterlinkedin about our vision our mission our team our values our partners faq terms  conditions privacy policy board news latest board news board news by location… europe usa  canada middle east all the others board news by company type public  listed vc  pe backed privately held trust  fund  reit board news by industry… life sciences  health care financials information technology women on board submit a press release board directory company press releases public  listed global  fortune  private or vc  pe backed unicorns trust  fund newsletter contact log in register select pageabout    our vision our mission     our team     our values     our partners     faq     terms  conditions     privacy policy board news    latest board news     board news by location…        europe         usa  canada         middle east         all the others     board news by company type        public  listed         vc  pe backed         privately held         trust  fund  reit     board news by industry…        life sciences  health care         financials         information technology     women on board     submit a press release board directory    company press releases     public  listed     global      fortune      private or vc  pe backed     unicorns     trust  fund newsletter contact log in register homeboard  usa  can board vcpe backed companies irhythm technologies announces tiba aynechi to its board after closing m series e financing led by novo as irhythm technologies announces tiba aynechi to its board after closing m series e financing led by novo as may   by talentboards team comments are off board  usa  can board vcpe backed companies – usa ca –  irhythm technologies inc a healthcare information services company today announced that it closed a  million series e financing led by novo as a global life science investment firm norwest venture partners which led the company’s series d financing also participated in the oversubscribed round irhythm’s zio service has been used with almost  patients at over  institutions nationwide and is covered by leading public and private insurers since its launch in  the company will use the proceeds to further accelerate market growth for its zio service expand technology development and continue to establish clinical evidence supporting its flagship solution “we are pleased to have novo as as a new investor and with this funding we are poised to further accelerate our company’s growth” said kevin king president and chief executive officer of irhythm “our zio service is setting a new standard for longterm continuous cardiac monitoring of patients with suspected arrhythmia we believe our strong and growing success with physicians and payers underscores the zio service’s compelling value proposition of using novel technology to improve diagnosis of cardiac arrhythmias while also increasing the efficiency of healthcare delivery” the zio service enables longterm continuous monitoring using the noninvasive small wearable zio patch combined with proprietary algorithms and the zio report to detect cardiac arrhythmias these heart rhythm disturbances often occur infrequently and without symptoms and may lead to serious complications if not detected and treated properly the zio patch enables continuous monitoring for up to  days and the solution is proven in multiple peerreviewed published studies to improve cardiac arrhythmia diagnosis and change patient management compared to traditional approaches to ambulatory electrocardiogram ecg monitoring multiple new studies were presented recently at heart rhythm  the heart rhythm society’s th annual scientific sessions supporting the use of the zio service to identify atrial fibrillation af and other cardiac arrhythmias these include a study that found the zio service identified nearly five times as many cases of af in the same amount of study time compared to the traditional holter monitor irhythm also announced that tiba aynechi phd principal at novo ventures us inc has joined the company’s board of directors dr aynechi has more than  years of combined research banking and venture capital experience in life sciences that spans various therapeutic areas and technology platforms “with its disruptive yet proven technology irhythm has established itself as the global leader in longterm continuous cardiac monitoring with the potential to improve diagnosis for the millions of patients each year who present with suspected arrhythmia” said dr aynechi “we believe the company with its vast technology capabilities is poised to create the world’s largest and highest quality cardiac rhythm data sets to further revolutionize patient care” about irhythm technologies inc irhythm is a privately held healthcare information services company that aspires to be the world leader in the management of cardiac arrhythmia information a large and growing unmet clinical need its flagship solution the zio service offers a proven approach to longterm continuous monitoring that enables diagnosis earlier in the clinical pathway to improve patient outcomes and reduce healthcare costs  disclaimer  news data and statement included in this release are intended exclusively for information purposes product and brand names used in this release maybe trademarks or registered trade marks of their respective owners talentboards accepts neither liability for the consequences of the reader’s reliance nor responsibility for the adequacy or accuracy of this release no data or statement in this release should be considered a recommendation for the purchase retention or sale of the securities referred to hereinother related postsirhythm technologies appoints bruce bodaken and dr ralph snyderman to its board of directorsinfobionic appoints hamid tabatabaie to its board of directorsvytronus announces david mcintyre sami hamade and hank kucheman to its board after securing m series b financing comments are closed latest boardroom news quintilesims appoints colleen goggins to its board of directors july   fuel tech announces ceo vincent arnone to additional role of chairman of the board of directors july   amphenol appoints john craig to its board of directors july   marine products appoints pam rollins to the board of directors july   avalonbay communities announces upcoming appointment of steve hills to its board of directors july   random boardsmbl grouplondon  associated propertiesepcylon technologiesallergy therapeuticsspire formerly the laclede group    talentboards inc  all rights reserved  geneva  miami  london  boston  paris  shanghai  monaco  tiba aynechi phd executive profile  biography  bloomberg july    am et capital markets company overview of novo ventures snapshotpeople  overviewboard memberscommittees executive profile tiba aynechi phdpartner novo venturesagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background dr tiba aynechi phd is a partner at novo as dr aynechi is responsible for supporting portfolio companies as well as investment and exit decisions through scientific due diligence strategic and financial analyses she joined novo as in  where she was previously an associate and a principal she served as a director of merchant banking at burrill  company since  where she completed regional and crossborder merger and acquisitions licensing and financing  transactions for biotech and large pharmaceutical companies she served as senior associate at burrill  company she served as an associate at burrill  company she joined burrill merchant banking in june  and was involved in assisting biotech companies in merger and acquisition and partnering transactions prior to joining burrill  company she was a postdoctoral fellow at the university of california san francisco her research involved developing computational methods for drug discovery dr aynechi served as director of anaptysbio inc since april  cianna medical inc since may  she serves as a director of nkarta inc battersea spruce biosciences and encarta arcellx she served as a director of irhythm technologies inc from may  to april   she served as a director of thesan pharmaceuticals inc she is also a published author of scientific articles and book chapters in the area of rational drug design she has more than  years of combined research and banking experience in life sciences that spans various therapeutic areas and technology platforms she holds phd from the graduate group in biophysics from the university of california san francisco in  and an undergraduate degree in physics from university of california irvineread full background corporate headquarters tuborg havnevej hellerup  dkdenmarkphone     fax      board members memberships directorthesan pharmaceuticals incpresentdirectorcianna medical inc education phd university of californiasan franciscobachelors degree university of california irvine other affiliations novo asuniversity of californiasan franciscouniversity of california irvineanaptysbio incburrill  companyirhythm technologies inccianna medical incthesan pharmaceuticals inc annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact novo ventures please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close